GFAP and Alzheimer disease: This suggests that GFAP, which is a non‐specific marker of neurodegeneration, may capture certain aspects of Alzheimer's pathology downstream effect that p‐tau217 alone does not, providing a more nuanced understanding of biomarker dynamics in preclinical AD.